Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Duolingo Inc (DUOL) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Duolingo IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Duolingo Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Duolingo Inc trades at $134.23 (market cap $6.34B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.7× Duolingo Inc's market cap, and Duolingo Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYDUOL
Market Cap
$29.60B$6.34B
Sector
HealthTechnology
52-Week High
$491.22$369.19
52-Week Low
$205.48$90.03
Enterprise Value
$27.56B$5.11B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

Duolingo Inc

Duolingo (DUOL) trades at $134.63, down 1.87% amid mixed signals. The stock shows strong fundamentals with impressive revenue growth from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $134 and resistance at $138. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.

The outlook remains cautiously optimistic with robust user growth and profitability metrics, but near-term pressure exists from decelerating booking growth and margin concerns. Analyst consensus is mixed with 30% buy ratings and a $121 price target below current levels. Key risks include monetization challenges despite user growth and increased competitive pressures in the education technology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL